This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bronstein, Gewirtz & Grossman, LLC Investigates Miller Energy Resources, Inc.

Headline of release should read: Bronstein, Gewirtz & Grossman, LLC Investigates Pain Therapeutics, Inc. (sted Bronstein, Gewirtz & Grossman, LLC Investigates Miller Energy Resources, Inc.).

The corrected release reads:

BRONSTEIN, GEWIRTZ & GROSSMAN, LLC INVESTIGATES PAIN THERAPEUTICS, INC.

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Pain Therapeutics, Inc. (“Pain Therapeutics” or the “Company”) (NasdaqGS: PTIE), concerning whether the company and certain of its officers and directors have violated federal securities laws.

On June 27, 2011 shares of Pain Therapeutics fell 26 percent after the company said manufacturing issues for a painkiller developed with Pfizer Inc. may delay regulatory approval by a year or “significantly longer.” Pain Therapeutics dropped $1.37 to $3.93 at 4 p.m. New York time. The shares tumbled 43 percent on June 24 after the Austin, Texas-based developer disclosed the delay of the painkiller, called Remoxy.

The Food and Drug Administration postponed clearance of the medicine, designed to curb drug abuse, after finding inconsistent results during laboratory tests of batches of the medicine, Pain Therapeutics said in a statement. The inconsistencies may be the result of a manufacturing deficiency or a flaw in the testing method, the company said. “Sufficient information does not yet exist to accurately assess the time required to resolve the concerns raised” by the FDA, Pain Therapeutics said. “Potential regulatory approval of Remoxy in the U.S. is unlikely to occur in less than one year, and could be delayed significantly longer.”

If you are aware of any facts relating to this investigation, or purchased shares of Pain Therapeutics, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate work, private securities offerings, and securities arbitration.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs